Overview
No overview information available.
Indication
用于防治缺硒引起的疾病,如克山病,大骨节病等。
Associated Conditions
No associated conditions information available.
Research Report
A Comprehensive Monograph on Sodium Selenite: Chemical Properties, Pharmacological Profile, and Clinical Significance
1.0 Introduction and Compound Identification
1.1 Overview of Sodium Selenite as an Inorganic Selenium Source
Sodium selenite is an inorganic salt that serves as a primary source of the essential trace element selenium. It is utilized across a spectrum of applications, ranging from a nutraceutical in dietary supplements to a therapeutic agent in clinical and veterinary medicine, and as a component in industrial processes.[1] As a chemical entity, it is defined by the duality of its biological role: selenium is indispensable for human health at low, physiological concentrations, yet it exhibits significant toxicity at higher doses.[4] This narrow therapeutic index is a central theme in its pharmacology and toxicology. In medicine, sodium selenite is investigated for its potential antineoplastic activity, a function that contrasts sharply with its role in maintaining cellular homeostasis, setting the stage for a complex, dose-dependent mechanism of action.[1]
1.2 Comprehensive Chemical and Physical Profile
The anhydrous form of sodium selenite is a well-characterized inorganic compound. It is a white or colorless crystalline solid, though it may also be supplied as a beige powder.[1] There is some discrepancy in the literature regarding its hygroscopic nature; while several sources describe it as a hygroscopic solid that readily absorbs moisture from the air, at least one supplier datasheet indicates it is not.[1] This variability may be attributable to differences in sample purity or experimental conditions and underscores the importance of controlled storage for maintaining the compound's integrity.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2020/03/05 | Phase 1 | Withdrawn | |||
2014/07/09 | Phase 1 | Completed | |||
2013/12/05 | Phase 3 | UNKNOWN | Daren K. Heyland | ||
2013/10/10 | Phase 1 | UNKNOWN | Karolinska University Hospital | ||
2011/09/28 | Phase 3 | Completed | |||
2010/06/10 | Phase 3 | Completed | University Hospital, Basel, Switzerland | ||
2005/09/16 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| JUNYELT CONCENTRATE FOR SOLUTION FOR INFUSION | N/A | N/A | N/A | 2/18/2019 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Ultimé Men's Prostate Support | 401470 | Medicine | A | 12/21/2022 | |
| BLACKMORES STAR MULTI | 382793 | Medicine | A | 1/19/2022 | |
| NUTRIWAY DOUBLE X - MINERAL SUPPLEMENT. | 289111 | Medicine | A | 5/18/2017 | |
| BLACKMORES MULTIVITAMINS + VITALITY | 374505 | Medicine | A | 9/10/2021 | |
| Joint formula advanced plus MSM | 355500 | Medicine | A | 2/24/2021 | |
| Joint Formula | 355499 | Medicine | A | 2/24/2021 | |
| Bio-Ridge NMN III 23180 | 349005 | Medicine | A | 11/19/2020 | |
| Bio-Ridge NMN III 15800 | 349010 | Medicine | A | 11/19/2020 | |
| OPTI CAPSULES | 474532 | Medicine | A | 12/23/2024 | |
| Nutura Infant Formulated Supplement 2 | 219865 | Functional Foods Global Pty Ltd | Medicine | A | 2/4/2014 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| FUSION AM FORMULA TAB | l & s research corporation | 01961152 | Tablet - Oral | 25 MCG / TAB | 12/31/1993 |
| MULTI MINERALS CAPSULES | sisu inc. | 00679003 | Capsule - Oral | 25 MCG / CAP | 12/31/1986 |
| ORTI-VITE CAP | seroyal international inc. | 00829382 | Capsule - Oral | 66.67 MCG | 12/31/1992 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.
